Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16882827 | 1.00 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2300360 | 1.00 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL21219895 | 0.91 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL178638 | 0.91 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22569401 | 0.91 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL23807724 | 0.91 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2267993 | 0.91 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Hydrochloric Acid SCHEMBL30260003 | 0.90 | CHRM2 (0.62) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Hydrochloric Acid SCHEMBL15058470 | 0.90 | CHRM2 (0.62) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Oxalic Acid SCHEMBL29539412 | 0.87 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305037-B1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4305037-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117177976-A | KRAS inhibitors | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM1 4883/4885CHRM3 4880/4885 |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | CHRM2 3695/4885CHRM1 4152/4885CHRM3 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.